You are viewing a free preview of this lesson.
Subscribe to unlock all 8 lessons in this course and every other course on LearningBro.
Spec mapping: AQA 7402 Section 3.6.4 — the liver as the principal detoxification and homeostatic regulatory organ, with focused coverage of deamination of excess amino acids, the ornithine (urea) cycle, ammonia handling, and the metabolic cost of urea synthesis (refer to the official AQA specification document for exact wording).
The liver is the organism's chemical processing plant. Every nutrient absorbed from the gut, every drug ingested, every potentially toxic metabolite produced by the body's own metabolism passes through the liver before reaching the systemic circulation. This first-pass position gives the liver an architectural advantage: it can modify, store, distribute or destroy molecules before they reach distant tissues. The liver performs more biochemical transformations than any other organ — over 500 distinct enzymatic reactions have been catalogued in hepatocytes. This lesson focuses on two themes drawn from the AQA specification: the detoxification of exogenous compounds (drugs, ethanol, environmental toxins) and the conversion of excess nitrogen from amino acid catabolism into urea, the principal nitrogenous excretory product in mammals.
Key Definition: Detoxification is the metabolic transformation of toxic, pharmacologically active or simply unwanted molecules into less harmful, more water-soluble products that can be excreted by the kidney or biliary route. The ornithine (urea) cycle is the metabolic pathway by which the liver converts toxic ammonia (NH₃) from amino acid deamination into non-toxic urea ((NH₂)₂CO) for renal excretion.
A grasp of the gross blood supply explains why the liver — uniquely among organs — operates with first-pass capability.
This portal architecture is unusual — most organs receive arterial blood and drain via veins to the heart. The liver's portal vein interposes a metabolic checkpoint between the gut and the rest of the body. The architectural consequence is that nothing absorbed from the gut reaches the systemic circulation unmodified — alcohol is partially metabolised before it ever reaches the brain, ingested drugs may be largely cleared before pharmacological effect, ammonia produced by gut bacteria is captured and converted to urea before reaching the brain (a failure of this capture in liver disease produces hepatic encephalopathy — ammonia toxicity to the central nervous system).
The liver is organised into lobules — hexagonal functional units centred on a central vein, with portal triads (portal vein branch, hepatic artery branch, bile duct) at each corner. Hepatocytes form plates radiating from the central vein outwards. Sinusoids between hepatocyte plates carry mixed portal and arterial blood. Bile is produced by hepatocytes and drains in the opposite direction, through bile canaliculi to the bile ducts.
Hepatic detoxification of foreign compounds (xenobiotics) and endogenous toxins proceeds in two enzymatic phases.
Phase I reactions are catalysed predominantly by the cytochrome P450 (CYP) superfamily — a family of haem-containing monooxygenases located in the smooth endoplasmic reticulum of hepatocytes. CYPs use molecular O₂ and NADPH to introduce or expose polar functional groups (hydroxyl, carboxyl, amino) on lipophilic substrates. Common reactions include:
The CYP family in humans contains ~50 active enzymes; CYP3A4 alone metabolises ~50% of pharmaceutical drugs in current use. Genetic variation in CYP expression and activity (CYP polymorphisms) underlies much of the inter-individual variation in drug response — a foundational concept in pharmacogenomics.
Phase I products are often more reactive than the parent compound; some are pharmacologically active and some are toxic. Phase I is therefore not "detoxification" in the literal sense — it is activation for clearance. The actual safe-disposal step is phase II.
Phase II reactions attach a water-soluble moiety to the phase I product, producing a highly polar conjugate that is readily excreted in bile or urine. Common conjugations:
Phase II products are usually pharmacologically inactive and readily excreted. The two-phase architecture (functionalise then conjugate) handles the chemical diversity of natural and synthetic toxins with remarkable economy.
Ethanol metabolism is the textbook detoxification example.
CYP2E1 provides a parallel oxidation pathway — significant at high blood ethanol concentrations and upregulated in chronic drinkers (a form of enzyme induction). The interplay between ADH and CYP2E1 explains why heavy drinkers metabolise ethanol faster than naive drinkers — and why CYP2E1 induction also accelerates paracetamol activation, making chronic drinkers more vulnerable to paracetamol overdose at lower doses.
Mammals cannot store excess amino acids beyond the metabolic protein pool. Dietary amino acids in excess of immediate need are deaminated in the liver, with the carbon skeletons entering general metabolism (glycolysis, the citric-acid cycle, gluconeogenesis, or ketogenesis) and the amino groups removed.
The principal deamination route is transamination followed by oxidative deamination of glutamate:
The net effect is conversion of an amino acid's amino group into ammonium ion, with carbon skeletons entering general metabolism. The keto acid products may enter gluconeogenesis (glucogenic amino acids — alanine becomes pyruvate, glutamate becomes α-ketoglutarate), ketogenesis (ketogenic amino acids — leucine and lysine), or both (most amino acids are both glucogenic and ketogenic in part).
Ammonium is highly toxic — particularly to the central nervous system, where it interferes with glutamate metabolism and ATP production. Free ammonia must be cleared rapidly. In mammals it is converted to urea via the ornithine cycle.
The urea cycle was the first metabolic cycle discovered, identified by Hans Krebs and Kurt Henseleit in 1932 (paraphrased — Krebs went on to discover the citric-acid cycle, also bearing his name). The pathway converts two molecules of ammonia (one from glutamate deamination, one from aspartate) and one molecule of carbon dioxide into one molecule of urea, regenerating the cycle intermediate ornithine.
flowchart LR
NH3[NH₃ + CO₂ + 2 ATP] --> CP[Carbamoyl phosphate]
CP --> Cit[Citrulline]
Orn[Ornithine] --> Cit
Cit --> ArgSuc[Argininosuccinate]
Asp[Aspartate + ATP] --> ArgSuc
ArgSuc --> Arg[Arginine]
ArgSuc -.->|fumarate released| Fum[Fumarate to citric acid cycle]
Arg --> Urea[Urea + ornithine]
Urea --> Excretion[Excreted in urine]
Arg --> Orn
The cycle's compartmentalisation is essential: steps 1 and 2 are mitochondrial; steps 3, 4 and 5 are cytosolic. Citrulline and ornithine cross the inner mitochondrial membrane on dedicated transporters. The architectural lesson is that pathway organisation is not merely chemical but spatial — the urea cycle exploits two compartments to separate steps with otherwise incompatible chemistry.
Each turn of the urea cycle consumes 4 high-energy phosphate bonds: 2 ATP at step 1 (carbamoyl phosphate synthesis) and 1 ATP → AMP (= 2 high-energy bonds) at step 3 (argininosuccinate synthesis). Producing one urea (carrying two nitrogen atoms) costs four high-energy phosphates. However, the fumarate released at step 4 enters the citric-acid cycle and is oxidised to malate then oxaloacetate, with NADH and FADH₂ yielding ATP via oxidative phosphorylation — recovering some of the cost. The net cost is therefore lower in practice than the gross 4 ATP figure suggests, but the cycle nonetheless represents a substantial metabolic expense — the price of converting toxic ammonia into safely excretable urea.
Urea produced in the liver diffuses into hepatic venous blood, joins the systemic circulation, and is delivered to the kidneys. There it is filtered freely at the glomerulus (lesson 1), partially reabsorbed in the proximal convoluted tubule and the collecting duct (urea contributes to the medullary concentration gradient — a synoptic link), and excreted in urine at the rate of approximately 25–30 g per day in a typical adult human eating a mixed Western diet.
Urea is the principal nitrogenous excretory product in mammals (and adult amphibians). Other animals use different end-products:
The choice of nitrogenous waste product reflects the same architectural trade-off that runs through this course: energetic cost vs water economy vs habitat constraint. Mammalian urea is one solution among several, no more "advanced" than the alternatives.
Genetic deficiencies of any urea-cycle enzyme produce urea-cycle disorders (UCDs) — rare inherited diseases characterised by hyperammonaemia (high blood ammonia). The most common is OTC deficiency, an X-linked recessive condition. Affected infants develop lethargy, vomiting, hyperventilation, seizures and coma within days of birth as dietary protein intake produces ammonia faster than the impaired cycle can clear it. Treatment combines protein restriction, alternative nitrogen-excretion pathways (sodium benzoate conjugates with glycine to form hippurate, excreted in urine), and in severe cases liver transplantation.
Hepatic failure (acute or chronic) reduces urea-cycle capacity. Blood ammonia rises, producing hepatic encephalopathy — confusion, asterixis, eventually coma. The brain is particularly vulnerable because ammonia disrupts the glutamate/glutamine cycle and depletes α-ketoglutarate, which is needed for the citric-acid cycle and ATP production in neurones. Treatment of hepatic encephalopathy includes lactulose (acidifies gut contents, trapping ammonia as ammonium) and rifaximin (reduces gut bacterial production of ammonia).
Subscribe to continue reading
Get full access to this lesson and all 8 lessons in this course.